OVERSEA CHINESE BANKING Corp Ltd Grows Stake in Illumina, Inc. (NASDAQ:ILMN)

OVERSEA CHINESE BANKING Corp Ltd boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 283,175 shares of the life sciences company's stock after acquiring an additional 16,055 shares during the quarter. Illumina accounts for 1.1% of OVERSEA CHINESE BANKING Corp Ltd's portfolio, making the stock its 21st biggest holding. OVERSEA CHINESE BANKING Corp Ltd owned 0.18% of Illumina worth $37,841,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. WCM Investment Management LLC increased its position in Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after acquiring an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Illumina by 0.8% during the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock valued at $454,617,000 after purchasing an additional 27,618 shares during the period. Geode Capital Management LLC grew its holdings in Illumina by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company's stock valued at $354,933,000 after purchasing an additional 48,018 shares during the period. Primecap Management Co. CA grew its holdings in Illumina by 3.6% during the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company's stock valued at $328,158,000 after purchasing an additional 87,599 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock valued at $282,735,000 after purchasing an additional 625,245 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Remove Ads

Illumina Trading Up 3.4 %

Shares of NASDAQ ILMN traded up $2.87 during midday trading on Friday, hitting $87.66. The company's stock had a trading volume of 3,822,397 shares, compared to its average volume of 2,097,701. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The business's 50 day moving average is $108.20 and its two-hundred day moving average is $128.27. Illumina, Inc. has a 12-month low of $80.18 and a 12-month high of $156.66. The firm has a market cap of $13.89 billion, a P/E ratio of -11.41, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ILMN shares. Royal Bank of Canada cut their price target on Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a report on Wednesday, March 12th. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Guggenheim dropped their price objective on Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Stephens reaffirmed an "overweight" rating and issued a $156.00 price objective on shares of Illumina in a research note on Tuesday, March 11th. Finally, HSBC lowered Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target for the company. in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Illumina currently has a consensus rating of "Moderate Buy" and an average target price of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.